Cadence Capital Management LLC lifted its position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) by 402.4% in the third quarter, Holdings Channel reports. The institutional investor owned 142,150 shares of the medical equipment provider’s stock after acquiring an additional 113,854 shares during the quarter. Cadence Capital Management LLC’s holdings in Lantheus were worth $2,125,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $104,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $104,000. NumerixS Investment Technologies Inc increased its holdings in shares of Lantheus by 1,000.0% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock worth $113,000 after buying an additional 7,000 shares during the last quarter. Sun Life Financial INC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $140,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Lantheus during the 2nd quarter worth approximately $151,000. Institutional investors and hedge funds own 90.73% of the company’s stock.
NASDAQ:LNTH opened at $15.84 on Friday. The company has a debt-to-equity ratio of 4.76, a current ratio of 3.50 and a quick ratio of 2.87. The company has a market cap of $587.74 million, a P/E ratio of 15.84, a P/E/G ratio of 3.55 and a beta of 1.36. Lantheus Holdings Inc has a fifty-two week low of $12.59 and a fifty-two week high of $24.45.
LNTH has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a report on Wednesday, September 5th. ValuEngine upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a report on Monday, August 20th. Credit Suisse Group cut their price target on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Thursday, August 2nd. Wells Fargo & Co cut their price target on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, August 2nd. Finally, Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a report on Saturday, August 4th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company’s stock. Lantheus has a consensus rating of “Hold” and a consensus target price of $22.67.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
Featured Story: Conference Calls
Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings Inc (NASDAQ:LNTH).
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.